Fluorescent In Situ Hybridization As a Primary Test for HER2 Status in Breast Cancer: Controversies Reply

被引：4
|
作者：
Sauter, Guido [1 ]
Lee, James A. [2 ]
Slamon, Dennis J. [3 ]
Press, Michael F. [4 ,5 ]
机构：
[1] Univ Hamburg, Univ Med Ctr Hamburg Eppendorf, Dept Pathol, Hamburg, Germany
[2] Altarum Inst, Ann Arbor, MI USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, Keck Sch Med, Dept Pathol, Los Angeles, CA 90095 USA
[5] Univ Calif Los Angeles, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90095 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 05期
关键词：
COST-EFFECTIVENESS ANALYSIS; RECEPTOR; 2; ASSESSMENT; GENE AMPLIFICATION; IMMUNOHISTOCHEMICAL ASSAY; FISH; TRASTUZUMAB; CONCORDANCE; CARCINOMAS; EXPRESSION; HERCEPTEST;
D O I：
10.1200/JCO.2009.25.3930
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E85 / E88
页数：4
相关论文
共 50 条
  • [41] Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry
    Hicks, David G.
    LABMEDICINE, 2011, 42 (08): : 459 - 467
  • [42] Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment
    Kosa, Csaba
    Kardos, Laszlo
    Kovacs, Judit
    Szollosi, Zoltan
    PATHOLOGY RESEARCH AND PRACTICE, 2013, 209 (03) : 147 - 150
  • [43] Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas
    Rosa, F. E.
    Santos, R. M.
    Rogatto, S. R.
    Domingues, M. A. C.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2013, 46 (03) : 207 - 216
  • [44] HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
    Hanna, Wedad M.
    Rueschoff, Josef
    Bilous, Michael
    Coudry, Renata A.
    Dowsett, Mitch
    Osamura, Robert Y.
    Penault-Llorca, Frederique
    van de Vijver, Marc
    Viale, Giuseppe
    MODERN PATHOLOGY, 2014, 27 (01) : 4 - 18
  • [45] Evaluation of HER2 Gene Amplification in Breast Cancer Using Nuclei Microarray in Situ Hybridization
    Jiang, Huiyong
    Bai, Xiaoyan
    Zhang, Cheng
    Zhang, Xuefeng
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2012, 13 (05) : 5519 - 5527
  • [46] HER2 Status in Gastric Adenocarcinomas Assessed by Immunohistochemistry, Automated Silver-Enhanced In Situ Hybridization and Fluorescence In Situ Hybridization
    Kim, Aeri
    Bae, Jung Min
    Kim, Se Won
    Gu, Mi Jin
    Bae, Young Kyung
    KOREAN JOURNAL OF PATHOLOGY, 2010, 44 (05) : 493 - 501
  • [47] Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
    Arnould, L
    Denoux, Y
    MacGrogan, G
    Penault-Llorca, F
    Fiche, M
    Treilleux, I
    Mathieu, MC
    Vincent-Salomon, A
    Vilain, MO
    Couturier, J
    BRITISH JOURNAL OF CANCER, 2003, 88 (10) : 1587 - 1591
  • [48] Comparison of Fluorescence in situ Hybridization and Immunohistochemistry for Assessment of HER-2 Status in Breast Cancer Patients
    Wang, Lin
    Wang, Xiaobei
    Nie, Xiu
    Ma, Ling
    JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2009, 29 (03) : 354 - 358
  • [49] Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
    L Arnould
    Y Denoux
    G MacGrogan
    F Penault-Llorca
    M Fiche
    I Treilleux
    M C Mathieu
    A Vincent-Salomon
    M O Vilain
    J Couturier
    British Journal of Cancer, 2003, 88 : 1587 - 1591
  • [50] Correlation of immunohistochemistry-equivocal (2+) human epidermal growth factor receptor 2 (HER2) with fluorescence in situ hybridization (FISH) gene status in invasive breast cancer: Is FISH necessary for all HER2 equivocal breast cancer cases?
    Alswayyed, Mohammed
    KUWAIT MEDICAL JOURNAL, 2022, 54 (04): : 476 - 480
12345